{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cml&page=27",
    "query": {
      "condition": "Cml",
      "page": 27
    },
    "page_size": 10
  },
  "pagination": {
    "page": 27,
    "page_size": 10,
    "total_count": 972,
    "total_pages": 98,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cml&page=28&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cml&page=26&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-08T18:33:09.454Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02220985",
      "title": "Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Acute Biphenotypic Leukemia",
        "Acute Leukemia of Ambiguous Lineage",
        "Acute Undifferentiated Leukemia",
        "Allogeneic Hematopoietic Stem Cell Transplant Recipient",
        "Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Blastic Plasmacytoid Dendritic Cell Neoplasm",
        "Childhood Acute Lymphoblastic Leukemia in Remission",
        "Childhood Acute Myeloid Leukemia in Remission",
        "Donor",
        "Lymphoblastic Lymphoma",
        "Myelodysplastic Syndrome With Excess Blasts",
        "Myelodysplastic Syndrome With Excess Blasts-1",
        "Myelodysplastic Syndrome With Excess Blasts-2",
        "Recurrent Acute Lymphoblastic Leukemia",
        "Recurrent Acute Myeloid Leukemia",
        "Recurrent Childhood Acute Lymphoblastic Leukemia",
        "Recurrent Childhood Acute Myeloid Leukemia",
        "Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Refractory Acute Lymphoblastic Leukemia",
        "Refractory Acute Myeloid Leukemia",
        "Acute Lymphoblastic Leukemia in Remission",
        "Acute Myeloid Leukemia in Remission"
      ],
      "interventions": [
        {
          "name": "Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Peripheral Blood Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        },
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "Up to 60 Years"
      },
      "enrollment_count": 84,
      "start_date": "2015-03-23",
      "completion_date": "2025-05-01",
      "has_results": true,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-11-08T18:33:09.454Z",
      "location_count": 2,
      "location_summary": "Pittsburgh, Pennsylvania • Seattle, Washington",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02220985"
    },
    {
      "nct_id": "NCT00101816",
      "title": "Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myeloid Leukemia",
        "Blast Crisis"
      ],
      "interventions": [
        {
          "name": "Dasatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 124,
      "start_date": "2004-12",
      "completion_date": "2008-03",
      "has_results": true,
      "last_update_posted_date": "2010-08-10",
      "last_synced_at": "2026-11-08T18:33:09.454Z",
      "location_count": 23,
      "location_summary": "Birmingham, Alabama • Anaheim, California • Los Angeles, California + 20 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Vallejo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00101816"
    },
    {
      "nct_id": "NCT02181478",
      "title": "Intra-Osseous Co-Transplant of UCB and hMSC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Acute Myelogenous Leukemia",
        "Myelodysplastic Syndromes",
        "Myelofibrosis",
        "Relapsed Non-Hodgkin Lymphoma",
        "Refractory Non-Hodgkin Lymphoma",
        "Hodgkin Lymphoma",
        "Refractory Hodgkin Lymphoma",
        "Relapsed Chronic Lymphocytic Leukemia",
        "Refractory Chronic Lymphocytic Leukemia",
        "Lymphoid Malignancies",
        "Chronic Myelogenous Leukemia"
      ],
      "interventions": [
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "total-body irradiation",
          "type": "RADIATION"
        },
        {
          "name": "cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "umbilical cord blood transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "mesenchymal stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 6,
      "start_date": "2015-07-22",
      "completion_date": "2020-02-07",
      "has_results": false,
      "last_update_posted_date": "2020-12-04",
      "last_synced_at": "2026-11-08T18:33:09.454Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02181478"
    },
    {
      "nct_id": "NCT00053963",
      "title": "FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Blastic Phase Chronic Myelogenous Leukemia",
        "Childhood Central Nervous System Germ Cell Tumor",
        "Childhood Choroid Plexus Tumor",
        "Childhood Chronic Myelogenous Leukemia",
        "Childhood Craniopharyngioma",
        "Childhood Grade I Meningioma",
        "Childhood Grade II Meningioma",
        "Childhood Grade III Meningioma",
        "Childhood High-grade Cerebral Astrocytoma",
        "Childhood Infratentorial Ependymoma",
        "Childhood Low-grade Cerebral Astrocytoma",
        "Childhood Spinal Cord Neoplasm",
        "Childhood Supratentorial Ependymoma",
        "Recurrent Childhood Acute Lymphoblastic Leukemia",
        "Recurrent Childhood Acute Myeloid Leukemia",
        "Recurrent Childhood Brain Stem Glioma",
        "Recurrent Childhood Cerebellar Astrocytoma",
        "Recurrent Childhood Cerebral Astrocytoma",
        "Recurrent Childhood Ependymoma",
        "Recurrent Childhood Medulloblastoma",
        "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor",
        "Recurrent Childhood Visual Pathway and Hypothalamic Glioma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Relapsing Chronic Myelogenous Leukemia",
        "Unspecified Childhood Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "romidepsin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 30,
      "start_date": "2002-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-16",
      "last_synced_at": "2026-11-08T18:33:09.454Z",
      "location_count": 1,
      "location_summary": "Arcadia, California",
      "locations": [
        {
          "city": "Arcadia",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00053963"
    },
    {
      "nct_id": "NCT07638007",
      "title": "Impact of Targeted Therapy on Cancer-Related Cognitive Impairment",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Disease/Condition Name Cancer-related Cognitive Dysfunction",
        "Chronic Lymphocytic Leukemia (CLL)",
        "Chronic Myeloid Leukemia, BCR-ABL1 Positive"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Rochester NCORP Research Base",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 400,
      "start_date": "2025-11-21",
      "completion_date": "2029-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-06-10",
      "last_synced_at": "2026-11-08T18:33:09.454Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07638007"
    },
    {
      "nct_id": "NCT00053287",
      "title": "Fludarabine/Carboplatin/Topotecan w/Thalidomide for Relapsed/Refractory AML, CML and MDS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Diseases"
      ],
      "interventions": [
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "thalidomide",
          "type": "DRUG"
        },
        {
          "name": "topotecan hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2002-09",
      "completion_date": "2007-03",
      "has_results": false,
      "last_update_posted_date": "2010-06-10",
      "last_synced_at": "2026-11-08T18:33:09.454Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00053287"
    },
    {
      "nct_id": "NCT02381548",
      "title": "Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Acute Myeloid Leukemia Post Cytotoxic Therapy",
        "Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive",
        "Myelodysplastic Syndrome",
        "Recurrent Adult Acute Myeloid Leukemia",
        "Recurrent Chronic Myeloid Leukemia, BCR-ABL1 Positive",
        "Refractory Acute Myeloid Leukemia",
        "Refractory Chronic Myeloid Leukemia, BCR-ABL1 Positive",
        "Secondary Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Adavosertib",
          "type": "DRUG"
        },
        {
          "name": "Belinostat",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2015-08-18",
      "completion_date": "2018-05-23",
      "has_results": false,
      "last_update_posted_date": "2026-01-30",
      "last_synced_at": "2026-11-08T18:33:09.454Z",
      "location_count": 2,
      "location_summary": "Tampa, Florida • Richmond, Virginia",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02381548"
    },
    {
      "nct_id": "NCT07909733",
      "title": "Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCT",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "High-risk Myeloid Malignancy",
        "Allogenic Stem Cell Transplantation",
        "Acute Myeloid Leukemia (AML)",
        "Chronic Myeloid Leukemia (CML)",
        "Primary Myelofibrosis (PMF)",
        "Intermediate-risk Myelodysplastic Syndrome",
        "High-risk Myelodysplastic Syndrome (MDS)",
        "Very High Risk Myelodysplastic Syndrome",
        "Secondary Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "imetelstat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 27,
      "start_date": "2027-02",
      "completion_date": "2031-02",
      "has_results": false,
      "last_update_posted_date": "2026-11-02",
      "last_synced_at": "2026-11-08T18:33:09.454Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07909733"
    },
    {
      "nct_id": "NCT06398457",
      "title": "Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Hematologic Malignancy",
        "Bone Marrow Transplant Rejection",
        "Acute Myeloid Leukemia (AML)",
        "Myelodysplastic Syndromes (MDS)",
        "Acute Lymphoblastic Leukemia (ALL), Adult",
        "Multiple Myeloma",
        "Aplastic Anemia",
        "Lymphoma",
        "Non Hodgkin Lymphoma",
        "Hodgkin Lymphoma",
        "Chronic Myeloid Leukemia",
        "Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "Darzalex Faspro (Daratumumab and hyaluronidase-fihj)",
          "type": "DRUG"
        },
        {
          "name": "JH-DSA Semi-Quant Screen and Response Score",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2024-09-19",
      "completion_date": "2028-03",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-11-08T18:33:09.454Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06398457"
    },
    {
      "nct_id": "NCT00666211",
      "title": "Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors",
        "Chronic Myeloproliferative Disorders",
        "Leukemia",
        "Lymphoma",
        "Lymphoproliferative Disorder",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasms",
        "Pain",
        "Precancerous Condition",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "educational intervention",
          "type": "OTHER"
        },
        {
          "name": "Titrated pain management",
          "type": "OTHER"
        },
        {
          "name": "questionnaire administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 98,
      "start_date": "2005-05",
      "completion_date": "2010-05",
      "has_results": true,
      "last_update_posted_date": "2012-09-06",
      "last_synced_at": "2026-11-08T18:33:09.454Z",
      "location_count": 11,
      "location_summary": "Hopkinsville, Kentucky • Owensboro, Kentucky • Chattanooga, Tennessee + 4 more",
      "locations": [
        {
          "city": "Hopkinsville",
          "state": "Kentucky"
        },
        {
          "city": "Owensboro",
          "state": "Kentucky"
        },
        {
          "city": "Chattanooga",
          "state": "Tennessee"
        },
        {
          "city": "Crossville",
          "state": "Tennessee"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00666211"
    }
  ]
}